Pharmacokinetics of Pegfilgrastim
- 1 August 2003
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (8P2) , 9S-14S
Abstract
Pegfilgrastim is a granulocyte colony‐stimulating factor (G‐CSF) with a long half‐life and sustained duration of action. Pegfilgrastim is created with pegylation technology, whereby a 20‐kD polyethylene glycol moiety is conjugated to filgrastim (recombinant human G‐CSF), resulting in a larger molecule. Consequently, its renal clearance by glomerular filtration is minimized, making neutrophil‐mediated clearance the predominant route of elimination. Preclinical animal data have shown that the clearance of pegfilgrastim depends on dosage and absolute neutrophil count, with pegfilgrastim having a longer circulating half‐life and more sustained duration of action than filgrastim. The biologic effect of pegfilgrastim is prolonged in a neutropenic setting because few mature neutrophils are available to mediate its elimination. Clinical trials have suggested that neutrophil‐mediated clearance of pegfilgrastim may be self‐regulating and may therefore be specific to each patient's hematopoietic recovery.Keywords
This publication has 13 references indexed in Scilit:
- Pegylation: Engineering Improved Biopharmaceuticals for OncologyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Safety and Efficacy of Pegfilgrastim in Patients Receiving Myelosuppressive ChemotherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyAnnals of Oncology, 2003
- Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancerAnnals of Oncology, 2002
- Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast CancerJournal of Clinical Oncology, 2002
- Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving ChemotherapyJournal of Clinical Oncology, 2000
- A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humansExperimental Hematology, 1999
- Granulocyte colony-stimulating factor and its receptorBlood, 1991
- Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.Journal of Clinical Investigation, 1988
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966